Early January 2026: Oral Wegovy expected to be available in pharmacies and via select telehealth providers, according to Novo Nordisk
No FDA black-box screen, no mental health, no eating disorder, no substance use, no allergies, no medications, no pregnancy
Mechanism: Why these drugs work (and why they cause problems) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially approved in 2005 for the treatment of type 2 diabetes
our team is here to guide you
Personalized food and supplement recommendations are then designed to enhance beneficial microbial activity, including activities that help support GLP-1 production
A1C less than 6.5% was achieved in up to 82% of the participants, and A1C of less than 5.7% was achieved up to 31% of the participants. In terms of the effect of retatrutide on body weight, Dr